What is the clinical evidence from this study?

Study design: Review. Population: Dyslipidemia. Intervention: AHA/ACC 2026 guidelines vs. ESC 2025 guidelines.

What question did this study set out to answer?

This review aims to critically compare the AHA/ACC 2026 dyslipidemia management guidelines with the ESC 2025 guidelines.

May 15, 2026Acta AngiologicaOpen Access

What’s new in the AHA/ACC 2026 guidelines for the management of dyslipidemia?

View Full Paper

Ask AI

Bookmark

Key result

AHA/ACC and ESC dyslipidemia guidelines diverge on risk assessment and treatment thresholds despite shared evidence.

Design

Review

Authors

BCBeata ChełstowskaCardinal Stefan Wyszyński University in Warsaw AKAdam KobayashiCardinal Stefan Wyszyński University in Warsaw MKMartyna Kopiec-OstrowskaCardinal Stefan Wyszyński University in Warsaw

Discussion

Member takes

Implication

This review highlights fundamental differences in clinical philosophy and decision-making between the AHA/ACC 2026 and ESC 2025 dyslipidemia guidelines, which may influence real-world cardiovascular prevention strategies.

Key Points

This review aims to critically compare the AHA/ACC 2026 dyslipidemia management guidelines with the ESC 2025 guidelines.
Comparative analysis of the AHA/ACC 2026 and ESC 2025 guidelines on dyslipidemia management.
Evaluation of differences in risk assessment, treatment thresholds, and decision-making frameworks.
Focus on implications for clinical practice, particularly in primary prevention and special populations.
AHA/ACC guidelines emphasize early intervention and individualized models using PREVENT risk equations and coronary artery calcium (CAC).
ESC guidelines maintain a target-driven approach based on predefined risk categories.
Significant differences are identified that could influence real-world cardiovascular prevention strategies.

PICO

Population

Dyslipidemia

Exposure / Comparator

AHA/ACC 2026 guidelines vs ESC 2025 guidelines

Cite This Study

Chełstowska et al. (2026) conducted a review in Dyslipidemia. AHA/ACC 2026 guidelines vs. ESC 2025 guidelines was evaluated. The AHA/ACC 2026 and ESC 2025 dyslipidemia guidelines differ fundamentally in clinical philosophy, risk assessment, and treatment thresholds despite shared evidence.

synapsesocial.com/papers/6a06b74ce7dec685947aa3ec https://doi.org/10.5603/aa.111819

View Full Paper

Ask AI

Bookmark

What’s new in the AHA/ACC 2026 guidelines for the management of dyslipidemia?

Discussion

Member takes

Implication

Key Points

PICO

Cite This Study

What’s new in the AHA/ACC 2026 guidelines for the management of dyslipidemia?

Discussion

Member takes

Implication

Key Points

PICO

Cite This Study

Also Consider

Also Consider